Foghorn Therapeutics (FHTX) EBIT Margin (2020 - 2026)
Foghorn Therapeutics' (FHTX) quarterly EBIT Margin came in at 660.33% in Q1 2026, down 27537.0% year-on-year from N/an in Q1 2025, and down 155.72% quarter-over-quarter from 258.22% in Q4 2025.
Foghorn Therapeutics (FHTX) EBIT Margin (2020 - 2026) Analysis & Trends
Foghorn Therapeutics' EBIT Margin history runs 7 years deep, the most recent figure standing at 660.33% for Q1 2026.
- On a quarterly basis, EBIT Margin fell 27537.0% year-over-year to 660.33% in Q1 2026; TTM through Mar 2026 was 301.34%, a 11307.0% increase from a year earlier, with the FY2025 full-year figure at 279.49%, up 17481.0% from the prior year.
- EBIT Margin slipped to 660.33% in Q1 2026 per FHTX's latest filing, from 258.22% in the prior quarter.
- Across five years, EBIT Margin topped out at 97.73% in Q3 2023 and bottomed at 840.51% in Q4 2024.
- The 5-year median for EBIT Margin is 441.29% (2023), against an average of 481.59%.
- Across the five-year window, EBIT Margin soared 6362525 bps in 2022 and plunged 39922 bps in 2024, its largest moves.
- Year by year, EBIT Margin stood at 762.09% in 2022, then surged by 42 bps to 441.29% in 2023, then tumbled by 90 bps to 840.51% in 2024, then soared by 69 bps to 258.22% in 2025, then plunged by 156 bps to 660.33% in 2026.
- Per Business Quant, the three latest FHTX EBIT Margin figures stand at 660.33% (Q1 2026), 258.22% (Q4 2025), and 226.92% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Foghorn Therapeutics | 352.57 Mn | 263.66 Mn | - | -660.33% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -660.33% |
| Dec 31, 2025 | -258.22% |
| Sep 30, 2025 | -226.92% |
| Jun 30, 2025 | -279.17% |
| Mar 31, 2025 | -384.96% |
| Dec 31, 2024 | -840.51% |
| Sep 30, 2024 | -305.48% |
| Jun 30, 2024 | -386.64% |
| Mar 31, 2024 | -558.30% |
| Dec 31, 2023 | -441.29% |
| Sep 30, 2023 | -97.73% |
| Jun 30, 2023 | -572.42% |
| Mar 31, 2023 | -627.56% |
| Dec 31, 2022 | -762.09% |
| Sep 30, 2022 | -425.97% |
| Jun 30, 2022 | -650.07% |
| Mar 31, 2022 | -709.29% |
| Dec 31, 2021 | -3,938.57% |
| Sep 30, 2021 | -64,051.22% |
| Jun 30, 2021 | -8,337.28% |